EBC-46, a novel PKC inhibitor shows pre-clinical potential
EBC-46, a novel PKC inhibitor shows pre-clinical potential
From wikimedia commons: http://upload.wikimedia.org/wikipedia/commons/thumb/b/b8/EBC-46.svg/310px-EBC-46.svg.png

A recent article published in Medical Express last week touts the impressive findings of a pre-clinical study on the experimental drug EBC-46 (pictured above). In the article, they claim that EBC-46 is able to effectively destroy tumors by destroying the blood vessels that supply it with oxygen and nutrients. It is important, however, to remember that the work they are reporting on is very preliminary and has yet to be shown to be safe or effective in humans. Many promising candidate drugs fail very early on in clinical trials because of an unforeseen side-effect or because the drug simply does not work as well in humans as in animal models.

Furthermore, EBC-46 may be a novel drug, but its target is nothing new. EBC-46 targets a protein called Protein Kinase C (PKC) that, when inhibited, prevents tumor cells from making proteins that help them live. PKC has been targeted by several compounds, with one, PMA getting a phase I clinical trial (safety and efficacy in a limited group of people with cancer). Unfortunately, PMA caused severe and life-threatening side effects and the trial was stopped.

Given the questionable history of PKC inhibitors, it has yet to be seen if EBC-46 will be safe to use in humans.

For the article upon which the press release was based see below:
Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models

Edited by SITN Waves Editor Adam Brown.

Save

166 thoughts on “New cancer drug promising, but has a long way to go

  1. There is an entire industry built around suing drug companies for their lies and deceit that injures and kills people for goshsakes.

    Thanks.

  2. When the have clinical trials for EBC-46 I def want in. I have been suffering with head and neck cancer for 13 yrs and the are running out of treatment options.

  3. what’s the difference if they do come out with this drug and they dispersed throughout the world what they will do is come up with something worse then cancer we already see this with CoV-19

  4. Astaxanthin + r-alpha Lipoic Acid

    Johanna Budwig (6 tablespoons cottage cheese..3 tablespoons Flax Oil)…blend 1 minute…grind 2 tablespoons Flax seeds fresh ground …mix w cottage cheese and dark berries blueberry strawberries apples..eat within 20 minutes…
    Get 20 minutes sunshine each day possible

    Nattokinase for reduced fibrinogen and cardio vascular health
    Research^^^^^these

  5. P.S.
    STELFONTA® (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment available for all grades of canine non-metastatic mast cell tumours (MCT)

    An efficacious dose was achieved and a Maximum Tolerated Dose (MTD) was not reached, indicating tigilanol tiglate tolerability in humans. Promising outcomes were attained in patients with a variety of solid tumour types, with a 27% treatment response, including 18% complete response (full tumour destruction). Following these positive results, a Phase I/II trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) is underway, with the first patient successfully dosed.

    First patient successfully dosed in QBiotics’ Phase I/II clinical trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC). Tigilanol tiglate is a novel, small molecule that is being tested as a single injection treatment for solid tumours. The Phase I/II clinical trial is a dose escalation study in HNSCC patients designed to determine optimal dosage, safety and tumour response. The QBC46-H03 trial is being run in Australia and India

    From qbiotics website

  6. EBC-46 now registered as Stelfonta has just been launched commercially in Europe for treatment of dogs cancers, marketed by Virbac. Still waiting on FDA, and very oddly, Australian authorities for approval. FDA was expected late Jan, early Feb but its now well into May. Human clinical trials for neck and other tumours underway in India/ Australia. Looking at breast cancer, a biggie, too
    MY issue is the ethical one of treating animals but not humans. Seems bizarre that EBC-46 obviously works but humans are denied life saving treatment, while their pet dogs can be treated. Am a little perplexed

    1. My dog was in an Australian EBC 46 trial for a small sarcoma on his toe. A perfectly healthy dog otherwise. He died a few hours after having the injection. I was not fully informed of the risk of this drug and devastated by his unnecessary death.

      1. Hi Maria
        Sorry to hear about your dog. When was this trial? Seems quite incredible that your dog died a few hours after treatment. Did they give an explanation?

        Regards and condolences

Leave a Reply

Your email address will not be published. Required fields are marked *